RDY:NYSE
Dr. Reddy's Laboratories
US$ 13,07
arrow_upward
+1,32%(+0,17) 1D
US$ 13,07
0,00% (0,00)
bedtimeAfter-market
Fechado: 16 de out., 16:00:07 GMT-4 · USD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para RDY…
Abrir
US$ 13,00
Alta
US$ 13,07
Baixa
US$ 12,94
Valor de mercado
10,81 bi
Volume médio
3,19 mi
Volume
2,79 mi
Dividendo
0,64%
Dividendo trimestral
US$ 0,02
Data de ex-dividendo
10 de jul. de 2026
Índice P/L
31,34
Alto — 52 sem
US$ 15,67
Baixo — 52 sem
US$ 11,36
LPA
US$ 0,42
Beta
0,30
Ações em circulação
834,64 mi
Nº de funcionários
28 mil
Abrir
US$ 13,00
Alta
US$ 13,07
Baixa
US$ 12,94
Valor de mercado
10,81 bi
Volume médio
3,19 mi
Volume
2,79 mi
Dividendo
0,64%
Dividendo trimestral
US$ 0,02
Data de ex-dividendo
10 de jul. de 2026
Índice P/L
31,34
Alto — 52 sem
US$ 15,67
Baixo — 52 sem
US$ 11,36
LPA
US$ 0,42
Beta
0,30
Ações em circulação
834,64 mi
Nº de funcionários
28 mil
Notícias
De fontes da web e parceiros de notícias
MarketBeat
·
há 1 hora
Dr. Reddy's Laboratories (NYSE:RDY) Stock Rating Raised to "Hold" at Wall Street Zen
CNBC TV18
·
há 21 horas
Pharma Stocks: Macquarie sees margin pressure in Q2, upgrades Dr Reddy’s and Alkem
ad-hoc-news.de
·
há 1 dia
Dr Reddy reports three FDA observations: what it means for Dr Reddy stock
Perfil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Sobre Dr. Reddy's Laboratories
CEOErez Israeli
Funcionários27,5 mil
Data de fundação1984
SedeHyderabad, Andra Pradexe, Índia
Setor-
Sitedrreddys.com